Free Submission Guide · Feb 2026 FDA Guidance · Section 524B
12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions
A practical, ungated guide to the most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions — what triggers each one, and exactly how to fix it before you submit.
Why cybersecurity is now the #1 hold on premarket clearance
Since Section 524B of the FD&C Act took effect, FDA has the explicit authority to refuse to accept any premarket submission for a cyber device that doesn’t meet cybersecurity requirements. With FDA’s Feb 3, 2026 final guidance now in force, and the Quality Management System Regulation (QMSR, 21 CFR Part 820) incorporating ISO 13485:2016 effective February 2, 2026, submissions that would have sailed through three years ago are now routinely held for cyber deficiencies — and an AI letter on cybersecurity can add months to your clearance timeline.
The patterns are predictable. After 250+ submissions with zero rejections, we see the same twelve issues come up again and again. This guide walks through each one: what reviewers see, why it’s flagged, and exactly how to fix it before you submit.
FDA Alignment
Every recommendation in this guide is aligned to FDA’s current final guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (issued February 3, 2026; supersedes the June 27, 2025 version), and to Section 524B of the FD&C Act.
How to use this guide
Read each reason as a self-assessment: do you have the artifact, and is it at the depth FDA expects?
Use the checklist at the end to score your submission readiness.
Where you find a gap, the fix list is concrete enough to start work on Monday.
The 12 Most Common Rejection Reasons
What FDA flags — and how to fix it before you submit
Each deficiency below is drawn from real submission cycles. An AI letter on any one of these can add 8–12 weeks to your clearance timeline.
01
1
Incomplete or shallow Software Bill of Materials (SBOM)
SBOM / Third-Party Components
👁 What reviewers see
Submission includes a high-level component list but is missing transitive dependencies, version pins, supplier identifiers, or a recognized format (SPDX/CycloneDX).
⚑ Why it’s flagged
FDA requires a machine-readable SBOM that supports vulnerability monitoring across the entire device lifecycle — not a static spreadsheet snapshot. Reviewers will issue a deficiency if they can’t trace third-party components or evaluate known vulnerabilities.
✓ How to fix it
Generate the SBOM in CycloneDX or SPDX format directly from your build pipeline.
Include all transitive dependencies, exact versions, suppliers, and license data.
Document the SBOM maintenance process: how it’s regenerated on each release and how vulnerabilities are tracked against it post-market.
02
2
Threat model not aligned to AAMI TIR57 or FDA expectations
Threat Modeling
👁 What reviewers see
Threat model is generic, lacks data flow diagrams with trust boundaries, or doesn’t connect identified threats to security controls and risk acceptance.
⚑ Why it’s flagged
FDA expects threat modeling that explicitly links assets, threats, vulnerabilities, and controls to patient safety risk. A STRIDE table without context or traceability rarely passes review.
✓ How to fix it
Build data flow diagrams that show every interface, trust boundary, and external entity.
Use a recognized methodology (STRIDE, PASTA) and tie each threat to a control or risk acceptance.
Cross-reference threats with the Security Risk Assessment and ISO 14971 risk file.
03
3
Security Risk Assessment not integrated with ISO 14971
Risk Management
👁 What reviewers see
Cybersecurity risks are tracked in a separate document with no link to the device’s safety risk management file.
⚑ Why it’s flagged
FDA’s premarket guidance is explicit: cybersecurity risk must be evaluated through the lens of patient safety. A standalone security risk register doesn’t demonstrate that link.
✓ How to fix it
Map each cybersecurity risk to a corresponding hazard and harm in the ISO 14971 file.
Document how exploitability is translated into a probability of harm.
Show the residual risk evaluation post-controls in both files consistently.
04
4
Secure Product Development Framework (SPDF) gaps
SPDF / QMS
👁 What reviewers see
Design controls don’t show evidence of security activities at each phase: requirements, design, implementation, verification, release.
Tell us about your device, your timeline, and your submission type. No sales pressure — just a clear, honest assessment and a fixed-price quote.
05
5
Penetration testing scoped too narrowly or with the wrong methodology
Penetration Testing
👁 What reviewers see
Pen test report covers only the web interface, uses automated scanning only, or was performed by a generalist firm without medical-device context.
⚑ Why it’s flagged
FDA expects testing that exercises every interface (wireless, USB, BLE, cellular, cloud, service ports) using a methodology appropriate to a medical device’s threat model.
✓ How to fix it
Scope pen testing across all device interfaces and the supporting cloud/back-end ecosystem.
Combine manual testing with automated tools; pure scans are insufficient.
Engage testers with documented medical-device experience and provide them the threat model.
06
6
Missing coordinated vulnerability disclosure plan
Post-Market / CVD
👁 What reviewers see
No published process for security researchers to report vulnerabilities, or no internal SLA for triage and remediation.
⚑ Why it’s flagged
FDA explicitly calls out coordinated vulnerability disclosure (CVD) as a required element of post-market cybersecurity. The absence of a documented program is a common deficiency.
✓ How to fix it
Publish a CVD policy with a security contact, scope, and response SLAs.
Define internal triage workflow tied to risk and patch release cadence.
Inadequate post-market cybersecurity monitoring plan
Post-Market Surveillance
👁 What reviewers see
Submission covers premarket controls but is silent on how vulnerabilities will be monitored, evaluated, and patched after clearance.
⚑ Why it’s flagged
FDA evaluates premarket and post-market cybersecurity together. Without a credible monitoring and patch plan, the premarket controls don’t stand on their own.
Cybersecurity labeling is now an explicit submission element per FDA’s Feb 3, 2026 guidance. Reviewers check that users and IT departments have what they need to operate the device safely.
✓ How to fix it
Include a dedicated cybersecurity section in IFU/labeling.
Document supported configurations, ports, protocols, and end-of-support dates.
Provide instructions for obtaining the SBOM and reporting vulnerabilities.
An SBOM is provided, but there’s no explanation of how it will be updated, validated, and shared across the product’s supported lifetime.
⚑ Why it’s flagged
An SBOM that’s accurate at submission but stale six months later doesn’t satisfy FDA’s intent. The lifecycle plan is just as important as the artifact itself.
✓ How to fix it
Describe how the SBOM is regenerated on every build and every release.
Document validation steps and the team accountable for accuracy.
Define how customers can request the current SBOM post-market.
10
10
Architecture views missing required detail
Security Architecture
👁 What reviewers see
Submission lacks global system view, multi-patient harm view, updateability view, or doesn’t show data flows and trust boundaries clearly.
⚑ Why it’s flagged
FDA’s Feb 3, 2026 final cybersecurity guidance (Appendix 2) is specific about the security architecture views required. Submissions that include only a single block diagram are routinely flagged.
✓ How to fix it
Provide all required views: global system, multi-patient harm, updateability/patchability.
Annotate trust boundaries, data classifications, and authentication points.
Keep diagrams consistent with the threat model and design documentation.
11
11
Cryptographic controls not justified or documented
Cryptography
👁 What reviewers see
Algorithms, key sizes, and key management are mentioned but not justified against modern standards; deprecated algorithms still in use.
⚑ Why it’s flagged
Reviewers expect a written cryptographic rationale: why each algorithm was chosen, where keys live, how they rotate, and how the design will age over the device’s lifetime.
✓ How to fix it
Document algorithms, key sizes, and protocols against NIST/FIPS guidance.
Describe key generation, storage, rotation, and destruction.
Plan for crypto-agility: how the device will move off deprecated algorithms in the field.
12
12
Update and patch mechanism not validated end-to-end
Update / Patch Management
👁 What reviewers see
The device can be updated, but there’s no validated process showing authenticity, integrity, rollback, and failure handling for updates in the field.
⚑ Why it’s flagged
Updateability is a required architecture view and a core post-market control. An unvalidated update path is one of the fastest ways to a deficiency letter.
All required architecture views (global, multi-patient harm, updateability)
10
Cryptographic rationale with key management and crypto-agility
11
Validated update mechanism with signature, integrity, and rollback testing
12
Traceability matrix tying every cyber artifact to design controls and the QMS
Effort Planning
Timeline Reality Check
Teams routinely underestimate cyber effort. Here’s what a complete cyber package typically takes for a moderate-complexity Class II connected device, when the work is done right the first time:
Note: Some artifacts run in parallel. Most teams need 10–14 weeks of focused work; rework after an AI letter typically adds 8–12 additional weeks to clearance.
Vendor Selection
When to bring in a specialist partner
You don’t need outside help for every submission. You probably do if any of these are true:
✓
This is your team’s first 510(k), De Novo, or PMA with cybersecurity in scope.
Want a senior expert to pressure-test your cyber package?
Book a free 30-minute strategy session. No sales rep, no obligation. We’ll review where you are, flag the gaps FDA is most likely to hit, and give you a fixed-fee quote within 48 hours.
